Logo

TwinStrand Biosciences: Gary Gilliland

Jan 06, 2021

Gary Gilliland has been appointed to the board of directors of Seattle-based TwinStrand Biosciences. Until February 2020, he was the president and director of the Fred Hutchinson Cancer Research Center. Prior to that, he was a professor at Harvard Medical School, director of the leukemia program at the Dana-Farber Cancer Institute, senior VP and global oncology franchise head at Merck, and vice dean of the Perlman School of Medicine at the University of Pennsylvania. Gilliland holds an MD from the University of California, San Francisco, and a PhD in microbiology from the University of California, Los Angeles.

Breaking News
The Scan

Open Pediatric Brain Tumor Atlas Team Introduces Genomic Data Collection, Analytical Tools

A study in Cell Genomics outlines open-source methods being used to analyze and translate whole-genome, exome, and RNA sequence data from the Pediatric Brain Tumor Atlas.

Neurological Outcomes Linked to Innate Immune Features After Cardiac Arrest

Researchers reporting in Med dig into immune features found a few hours after cardiac arrest that correspond with neurological outcomes.

Mouse Study Finds Circadian Rhythm-Related Gene Expression Changes Linked to Sleep Apnea

A paper in PLOS Biology reveals tissue-specific circadian rhythm and gene expression patterns in an intermittent hypoxia-based mouse model of obstructive sleep apnea.

Polygenic Risk Score to Predict Preeclampsia, Gestational Hypertension in Pregnant Women

Researchers in Nature Medicine provide new mechanistic insights into the development of hypertensive disorders of pregnancy, which may help develop therapeutics.